2D-DIGE proteome analysis on the platelet proteins of patients with major depression

Proteome Science

Volumn 12, Issue 1, 2014, Pages

  Huang, Tiao Lai ^a   Sung, Mei Lan ^a   Chen, Tai Yuan ^b  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b NATIONAL TAIWAN OCEAN UNIVERSITY   (Taiwan)

Author keywords

2D DIGE; Fibrinogen; Major depression; Platelet; Western blot

Indexed keywords

CHAPERONIN CONTAINING TCP1; F ACTIN CAPPING PROTEIN SUBUNIT BETA; FIBRINOGEN; FIBRINOGEN BETA CHAIN; FIBRINOGEN GAMMA CHAIN; GLUTATHIONE PEROXIDASE 1; PROTEIN; PROTEIN DISULFIDE ISOMERASE; PROTEIN DISULFIDE ISOMERASE A3; RETINOIC ACID RECEPTOR BETA; SH3 DOMAIN CONTAINING PROTEIN 19; T COMPLEX PROTEIN 1 SUBUNIT BETA; THROMBOCYTE PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BIOINFORMATICS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR DEPRESSION; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PROTEIN ANALYSIS; TWO DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS; WESTERN BLOTTING;

EID: 84892870380     PISSN: None     EISSN: 14775956     Source Type: Journal    
DOI: 10.1186/1477-5956-12-1     Document Type: Article

References (57)

1. Maes M. Evidence for an immune response in major depression: a review and hypothesis. Prog Neuropsychopharmacol Biol Psychiatry 1995, 19:11-38. 10.1016/0278-5846(94)00101-M, 7708925.
2. Maes M, Lambrechts J, Bosmans E, Jacobs J, Suy E, Vandervorst C, de Jonckheere C, Minner B, Raus J. Evidence for a systemic immune activation during depression: results of leukocyte enumeration by flow cytometry in conjunction with monoclonal antibody staining. Psychol Med 1992, 22:45-53. 10.1017/S0033291700032712, 1574566.
3. Maes M, Scharpe S, Van Grootel L, Uyttenbroeck W, Cooreman W, Cosyns P, Suy E. Higher alpha 1-antitrypsin, haptoglobin, ceruloplasmin and lower retinol binding protein plasma levels during depression: further evidence for the existence of an inflammatory response during that illness. J Affec Disord 1992, 24:83-192.
4. Hornig-Rohan M, Van Bell CT, Kuhn P, Amsterdam JD. Acute phase proteins in affective illness. Biol Psychiatry 1995, 37:607.
5. Hornig-Rohan M, Goodman DB, Kamoun M, Amsterdam JD. Immune dysfunction in affective subtypes. Biol Psychiatry 1996, 39:524.
6. Sluzewska A, Rybakowski JK, Bosmans E, Sobieska M, Berghmans R, Maes M, Wiktorowicz K. Indicators of immune activation in major depression. Psychiatry Res 1996, 64:161-167. 10.1016/S0165-1781(96)02783-7, 8944394.
7. Khawaja X, Xu J, Liang JJ, Barrett JE. Proteomic analysis of protein changes developing in rat hippocampus after chronic antidepressant treatment: implications for depressive disorders and future therapies. J Neurosci Res 2004, 75:451-460. 10.1002/jnr.10869, 14743428.
8. Tsai SJ. The possible role of tissue-type plasminogen activator and the plasminogen system in the pathogenesis of major depression. Med Hypotheses 2006, 66:319-322. 10.1016/j.mehy.2005.10.009, 16309851.
9. Tsai SJ. Statins may enhance the proteolytic cleavage of proBDNF: implications for the treatment of depression. Med Hypotheses 2007, 68:1296-1299. 10.1016/j.mehy.2006.09.043, 17097821.
10. Lee BH, Kim YK. Reduced platelet BDNF level in patients with major depression. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:849-853. 10.1016/j.pnpbp.2009.04.002, 19371767.
11. Mössner R, Mikova O, Koutsilieri E, Saoud M, Ehlis AC, Müller N, Fallqatter AJ, Riederer P. Consensus paper of the WFSBP Task Force on Biological Markers: biological markers in depression. World J Biol Psychiatry 2007, 8:141-174. 10.1080/15622970701263303, 17654407.
12. Ziegenhorn AA, Schulte-Herbrüggen O, Danker-Hopfe H, Malbranc M, Hartung HD, Anders D, Lang UE, Steinhagen-Thiessen E, Schaub RT, Hellweq R. Serum neurotrophins-a study on the time course and influencing factors in a large old age sample. Neurobiol Aging 2007, 28:1436-1445. 10.1016/j.neurobiolaging.2006.06.011, 16879899.
13. Karege F, Bondolfi G, Gervasoni N, Schwald M, Aubry JM, Bertschy G. Low brain-derived neurotrophic factor (BDNF) levels in serum of depressed patients probably results from lowered platelet BDNF release unrelated to platelet reactivity. Biol Psychiatry 2005, 57:1068-1072. 10.1016/j.biopsych.2005.01.008, 15860348.
14. Karege F, Perret G, Bondolfi G, Schwald M, Bertschy G, Aubry JM. Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Res 2002, 109:143-148. 10.1016/S0165-1781(02)00005-7, 11927139.
15. Lo L, Huang T, Shiea J. Acid hydrolysis followed by matrix-assisted laser desorption ionization mass spectrometry for rapid diagnosing of serum protein biomarkers in patients with major depression. Rapid Commun Mass Spectrom 2009, 23:589-598. 10.1002/rcm.3908, 19165777.
16. Tanaka K, Waki H, Ido Y, Akita S, Yoshida Y, Yoshida T, Matsuo T. Protein and polymer analyses up to m/z 100 000 by laser ionization time-of-flight mass spectrometry. Rapid Commun Mass Spectrom 1988, 2:151-153.
17. Nelson RW, Dogruel D, Willams P. Mass determination of human immunoglobulin IgM using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Rapid Commun Mass Spectrom 1994, 8:627-631. 10.1002/rcm.1290080811, 7949330.
18. Karas M, Hillenkamp F. Laser desorption ionization of proteins with molecular masses exceeding 10,000 daltons. Anal Chem 1988, 60:2299-2301. 10.1021/ac00171a028, 3239801.
19. Kondo T, Hirohashi S. Application of highly sensitive fluorescent dyes (CyDye DIGE Fluor saturation dyes) to laser microdissection and two-dimensional difference gel electrophoresis (2D-DIGE) for cancer proteomics. Nat Protoc 2006, 1:2940-2956.
20. Kondo T, Seike M, Mori Y, Fujii K, Yamada T, Hirohashi S. Application of sensitive fluorescent dyes in linkage of laser microdissection and two-dimensional gel electrophoresis as a cancer proteomic study tool. Proteomics 2003, 3:1758-1766. 10.1002/pmic.200300531, 12973736.
21. Maes M, Ruckoanich P, Chang YS, Mahanonda N, Berk M. Multiple aberrations in shared inflammatory and oxidative & nitrosative stress (IO&NS) pathways explain the co-association of depression and cardiovascular disorder (CVD), and the increased risk for CVD and due mortality in depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35:769-783. 10.1016/j.pnpbp.2010.06.008, 20561554.
22. Maes M, Scharpes S, Meltzer HY, Okayli G, Bosmans E, D'Hondt P, et al. Increased neopterin and interferon-gamma secretion and lower availability of L-tryptophan in major depression: further evidence for an immune response. Psychiatry Res 1994, 54:143-160. 10.1016/0165-1781(94)90003-5, 7761549.
23. Angerio AD. Interferon and heart disease. Crit Care Nurs Q 2009, 32:159-162. 10.1097/CNQ.0b013e3181a27ffb, 19300081.
24. Kim YK, Suh IB, Kim H, Han CS, Lim CS, Choi SH, et al. The plasma levels of interleukin-12 in schizophrenia, major depression, and bipolar mania: effects of psychotropic drugs. Mol Psychiatry 2002, 7:11071114.
25. Song C, Lin A, Bonaccorso S, Heide C, Verkerk R, Kenis G, et al. The inflammatory response system and the availability of plasma tryptophan in patients with primary sleep disorders and major depression. J Affect Disord 1998, 49:211-219. 10.1016/S0165-0327(98)00025-1, 9629951.
26. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, Lanctot KL. A meta-analysis of cytokines in major depression. Biol Phychiatry 2010, 67:446-457.
27. Schieoers OJ, Wichers MC, Maes M. Cytokines and major depression. Prog Neuropsycopharmacol Biol Psychiatry 2005, 29:201-217.
28. Maes M, Mihaylova I, Kubera M, Uytterhoeven M, Vrydags N, Bosmans E. Increased plasma peroxides and serum oxidized low density lipoprotein antibodies in major depression: markers that further explain the higher incidence of neurodegeneration and coronary artery disease. J Affect Disord 2010, 125:287-294. 10.1016/j.jad.2009.12.014, 20083310.
29. Chrapko WE, Jurasz P, Radomski MW, Lara N, Archer SL, Le Melledo JM. Decreased platelet nitric oxide synthase activity and plasma nitric oxide metabolites in major depressive disorder. Biol Psychiatry 2004, 56:129-134. 10.1016/j.biopsych.2004.03.003, 15231445.
30. Maes M, Mihaylova I, Kubera M, Leunis JC. An IgM-mediated immune response directed against nitro-bovine serum albumin (nitro-BSA) in chronic fatigue syndrome (CFS) and major depression: evidence that nitrosative stress is another factor underpinning the comorbidity between major depression and CFS. Neuro Endocrinol Lett 2008, 29:313-319.
31. Herken H, Gurel A, Selek S, Armutcu F, Ozen ME, Bullut M, et al. Adenosine deaminase, nitric oxide, superoxide dismutase, and xanthine oxidase in patients with major depression: impact of antidepressant treatment. Arch Med Res 2007, 38:247-252. 10.1016/j.arcmed.2006.10.005, 17227736.
32. Brunoni AR, Lopes M, Fregni F. A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression. Int J Neuropsychopharmacol 2008, 11:1169-1180. 10.1017/S1461145708009309, 18752720.
33. Ricken R, Adli M, Lange C, Krusche E, Koehler S, Hellweg R, Nase S, Richter C, Bschor T, Steinacher B, Rapp M, Borgwardt S, Lang UE. Reduced BDNF serum concentrations in acute depressive patients increased during lithium augmentation of antidepressants. J Clin Psychopharmacol 2013, in press.
34. Hock C, Heese K, Muller-Spahn F, Huber P, Riesen W, Nitsch RM, Otten U. Increased cerebrospinal fluid levels of neurotrophin 3 (NT-3) in elderly patients with major depression. Mol Psychiatry 2000, 5:510-513. 10.1038/sj.mp.4000743, 11032384.
35. Rosa AR, Frey BN, Andreazza AC, Cereser KM, Cunha AB, Quevedo J, Santin A, Gottfried C, Goncalves CA, Vieta E, Kapczinski F. Increased serum glial cell line-derived neurotrophic factor immunocontent during manic and depressive episodes in individuals with bipolar disorder. Neurosci Lett 2006, 407:146-150. 10.1016/j.neulet.2006.08.026, 16959421.
36. Evans SJ, Choudary PV, Neal CR, Vawter MP, Tomita H, Lopez JF, Thompson RC, Meng F, Stead JD, Walsh DM, Myers RM, Bunney WE, Watson SJ, Jones EG, Akil H. Dysregulation of the fibroblast growth factor system in major depression. Proc Natl Acad Sci USA 2004, 101:15506-15511. 10.1073/pnas.0406788101, 523463, 15483108.
37. Lang UE, Hellweg R, Bajbouj M, Gaus V, Sander T, Gallinat J. Gender-dependent association of a functional NGF polymorphism with anxiety-related personality traits. Pharmacopsychiatry 2008, 41:196-199. 10.1055/s-0028-1082070, 18763222.
38. Beaulieu JM. A role for Akt and glycogen synthase kinase-3 as integrators of dopamine and serotonin neurotransmission in mental health. Psychopharmacol 2010, 30:135-144.
39. Ackermann TF, Kempe DS, Lang F, Lang UE. Hyperactivity and enhanced curiosity of mice expressing PKB/SGK-resistant glycogen synthase-3 (GSK-3). Cell Physiol Biochem 2010, 25:775-786. 10.1159/000315097, 20511724.
40. Lang UE. Impairment of phosphatidylinositol 3-kinase signaling in schizophrenia: state or trait?. Am J Psychiatry 2010, 167:719.
41. Naito Y, Takagi T, Okada H, Omatsu T, Mizushima K, Handa O, Kokura S, Ichikawa H, Fujiwake H, Yoshikawa T. Identification of inflammation-related proteins in a murine colitis model by 2D fluorescence difference gel electrophoresis and mass spectrometry. J Gastroenterol Hepatol 2010, 25:S144-S148.
42. Bourdi M, Demady D, Martin JL, Jabbour SK, Martin BM, George JW, Pohl LR. cDNA cloning and baculovirus expression of the human liver endoplasmic reticulum P58: characterization as a protein disulfide isomerase isoform, but not as a protease or a carnitine acyltransferase. Arch Biochem Biophys 1995, 323:397-403. 10.1006/abbi.1995.0060, 7487104.
43. Garbi N, Tanaka S, Momburg F, Hämmerling GJ. Impaired assembly of the major histocompatibility complex class I peptide-loading complex in mice deficient in the oxidoreductase ERp57. Nat Immunol 2006, 7:93-102. 10.1038/ni1288, 16311600.
44. McHugh PC, Rogers GR, Loudon B, Glubb DM, Joyce PR, Kennedy MA. Proteomic analysis of embryonic stem cell-derived neural cells exposed to the antidepressant paroxetine. J Neurosci Res 2008, 86:306-316. 10.1002/jnr.21482, 17868153.
45. Vaccarino V, Brennan ML, Miller AH, Bremner JD, Ritchie JC, Lindau F, Veledar E, Su S, Murrah NV, Jones L, Jawed F, Dai J, Goldberg J, Hazen SL. Association of major depressive disorder with serum myeloperoxidase and other markers of inflammation: a twin study. Biol Psychiatry 2008, 64:476-483. 10.1016/j.biopsych.2008.04.023, 2597204, 18514165.
46. Danese A, Moffitt TE, Pariante CM, Ambler A, Poulton R, Caspi A. Elevated inflammation levels in depressed adults with a history of childhood maltreatment. Arch Gen Psychiatry 2008, 65:409-415. 10.1001/archpsyc.65.4.409, 2923056, 18391129.
47. Markovitz JH, Shuster JL, Chitwood WS, May RS, Tolbert LC. Platelet activation in depression and effects of sertraline treatment: an open-label study. Am J Psychiatry 2000, 157:1006-1008. 10.1176/appi.ajp.157.6.1006, 10831484.
48. Bilici M, Efe H, Köroǧlu MA, Uydu HA, Bekaroǧlu M, Deǧer O. Antioxidative enzyme activities and lipid peroxidation in major depression: alterations by antidepressant treatments. J Affect Disord 2001, 64:43-51. 10.1016/S0165-0327(00)00199-3, 11292519.
49. Srivastava N, Barthwal MK, Dalal PK, Agarwal AK, Nag D, Seth PK, Srimal RC, Dikshit M. A study on nitric oxide, beta-adrenergic receptors and antioxidant status in the polymorphonuclear leukocytes from the patients of depression. J Affect Disord 2002, 72:45-52. 10.1016/S0165-0327(01)00421-9, 12204316.
50. Kodydková J, Vávrová L, Zeman M, Jirák R, Macášek J, Staňková B, Tvrzická E, Žák A. Antioxidative enzymes and increased oxidative stress in depressive women. Clin Biochem 2009, 42:1368-1374. 10.1016/j.clinbiochem.2009.06.006, 19527700.
51. Lang UE, Borgwardt S. Molecular mechanisms of depression: perspectives on new treatment strategies. Cell Physiol Biochem 2013, 31:761-777. 10.1159/000350094, 23735822.
52. Bremner JD, McCaffery P. The neurobiology of retinoic acid in affective disorders. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:315-331. 10.1016/j.pnpbp.2007.07.001, 2704911, 17707566.
53. Misner DL, Jacobs S, Shimizu Y, de Urquiza AM, Solomin L, Perlmann T, De Luca LM, Stevens CF, Evans RM. Vitamin A deprivation results in reversible loss of hippocampal long-term synaptic plasticity. Proc Natl Acad Sci USA 2001, 98:11714-11719. 10.1073/pnas.191369798, 58795, 11553775.
54. Chen X, Meng Q, Bao A, Swaab DF, Wang G, Zhou J. The involvement of retinoic acid receptor in corticotropin-releasing hormone gene expression and affective disorders. Biol Psychiatry 2009, 66:832-839. 10.1016/j.biopsych.2009.05.031, 19596122.
55. Katsuki H, Kurimoto E, Takemori S, Kurauchi Y, Hisatsune A, Isohama Y, Izumi Y, Kume T, Shudo K, Akaike A. Retinoic acid receptor stimulation protects midbrain dopaminergic neurons from inflammatory degeneration via BDNF-mediated signaling. J Neurochem 2009, 110:707-718. 10.1111/j.1471-4159.2009.06171.x, 19457078.
56. Kino T, Jaffe H, Amin ND, Chakrabarti M, Zheng YL, Chrousos GP, Pant HC. Cyclin-dependent kinase 5 modulates the transcriptional activity of the mineralocorticoid receptor and regulates expression of brain-derived neurotrophic factor. Mol Endocrinol 2010, 24:941-952. 10.1210/me.2009-0395, 2870940, 20357208.
57. First MB, Spitzer RL, Gibbon M, Williams JBW. User's Guide for the Structured Clinical Interview for DSM-IV Axis I Disorders-Clinician Version (SCID-CV) 1997, Washington, DC: American Psychiatric Press.